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Abstract
Background: Systematic reporting of funding sources is recommended in the CONSORT Statement for abstracts.
However, no specific recommendation is related to the reporting of conflicts of interest (CoI). The objective was to
compare physicians’ confidence in the conclusions of abstracts of randomized controlled trials of pharmaceutical
treatment indexed in PubMed.
Methods: We planned a three-arm parallel-group randomized trial. French general practitioners (GPs) were invited
to participate and were blinded to the study’s aim. We used a representative sample of 75 abstracts of pharmaceutical
industry-funded randomized controlled trials published in 2010 and indexed in PubMed. Each abstract was
standardized and reported in three formats: 1) no mention of the funding source or CoI; 2) reporting the funding
source only; and 3) reporting the funding source and CoI. GPs were randomized according to a computerized
randomization on a secure Internet system at a 1:1:1 ratio to assess one abstract among the three formats. The
primary outcome was GPs’ confidence in the abstract conclusions (0, not at all, to 10, completely confident). The
study was planned to detect a large difference with an effect size of 0.5.
Results: Between October 2012 and June 2013, among 605 GPs contacted, 354 were randomized, 118 for each
type of abstract. The mean difference (95% confidence interval) in GPs’ confidence in abstract findings was
0.2 (−0.6; 1.0) (P = 0.84) for abstracts reporting the funding source only versus no funding source or CoI; −0.4
(−1.3; 0.4) (P = 0.39) for abstracts reporting the funding source and CoI versus no funding source and CoI; and −0.6
(−1.5; 0.2) (P = 0.15) for abstracts reporting the funding source and CoI versus the funding source only.
Conclusions: We found no evidence of a large impact of trial report abstracts mentioning funding sources or CoI on
GPs’ confidence in the conclusions of the abstracts.
Trial Registration: ClinicalTrials.gov identifier: NCT01679873
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Background
The source of funding of clinical trials and researchers’
conflicts of interest (CoI) are a major cause for concern
in clinical research. Several empirical studies showed that
pharmaceutical industry-funded trials more often report
positive conclusions than do non-industry–funded trials
[1-4]. Internal industry documents, which have become
public because of litigation, have revealed how industry
trials selectively report favorable results and modify the in-
terpretation of results to favor their drug [5,6]. Similarly,
the financial relationship among industry, scientific inves-
tigators and academic institutions can affect the presenta-
tion and interpretation of clinical trial results [7-11].
To deal with these issues, some initiatives have aimed to
increase transparency in medical research. The American
Medical Association encourages physicians to regularly
update all their financial and CoI disclosures required
by employers, advisory bodies and entities funding re-
search. The Physician Payment Sunshine Act requires
manufacturers of drugs, devices, biologicals or medical
supplies to report annually certain payments or other
transfers of value to physicians and teaching hospitals.
The manufacturers’ reports will be available on a public
searchable website [12]. The International Committee
of Medical Journal Editors (ICMJE) recommends that
all authors who submit a manuscript complete the ICMJE
Uniform Disclosure Form for Potential Conflicts of Interest
[13,14]. Finally, the CONSORT Statement for abstracts
recommends reporting the funding source in the abstract
of randomized trials and in the full-text articles [15,16].
However, despite these recommendations, the funding
source and CoI are frequently inadequately reported
[17-20]. For example, despite the CONSORT Statement
for abstracts, the funding source is reported in less than
20% of abstracts for randomized controlled trials (RCTs)
published in high-impact-factor journals [21], and author
CoI are usually not reported in abstracts for RCTs.
The reporting of the trial funding source and the
authors’ financial CoI could affect readers’ interpre-
tations. Some studies showed that disclosure of the
funding source or authors’ financial CoI in abstracts
can lead readers to discount the results of a trial [22,23].
Recently, Kesselheim and colleagues showed that the
reporting of industry funding in abstracts negatively
affected readers’ interpretations independent of the
trial’s quality [24]. However, most of these studies in-
volved a small number of abstracts representing hypo-
thetical scenarios of clinical trials evaluating a new
drug [24,25]. Furthermore, these studies did not com-
pare the effect of reporting both the trial funding
source and the authors’ financial CoI.
We aimed to compare the confidence of primary-care
physicians in the conclusions of a large representative
sample of abstracts for RCTs of pharmaceutical treatment
indexed in PubMed reported with or without mention of
the funding source and/or authors’ financial CoI.
Methods
Trial design
We planned a three-arm parallel-group RCT with a
sample of representative abstracts of RCTs of pharma-
ceutical treatment indexed in PubMed, each reported
with 1) no mention of the funding source or authors’
financial CoI, 2) the funding source only or 3) the funding
source and CoI.
We obtained ethics approval from the Institutional
Review Board of Paris Descartes University, Paris, France
(no. 2012-A00032-41), and the protocol is registered at
ClinicalTrials.gov (NCT01679873).
The study was funded by a grant from the Fondation
pour la RechercheMédicale (EquipeEspoir de la Recherche,
2010). The funders were not involved in the study design;
data collection, analysis, or interpretation; the writing of the
article; or the decision to submit for publication.
Selection of randomized controlled trials indexed in PubMed
We selected a sample of RCTs indexed in PubMed and
published from 1 January 2010 to 31 December 2010 in
the Core Clinical Journals (a subset of 119 widely read
journals published in English, covering all specialties of
clinical medicine and public-health sciences and including
all major medical journals). The search strategy is detailed
in Additional file 1. One researcher screened all retrieved
citations on the title, abstract and the full text when neces-
sary. The eligibility criteria were an industry-funded RCT
with at least one author having a financial CoI, testing
superiority, assessing pharmaceutical treatment (drugs)
prescribed in a primary-care setting (defined as drugs
that may be prescribed by a general practitioner (GP)
or prescribed for diseases managed jointly by a specialist
and a GP), with a conclusion in favor of the beneficial effect
of the experimental treatment.
Exclusion criteria were investigation of nonpharmaceuti-
cal treatments (that is, medical devices, patient education),
equivalence or noninferiority trials, safety trials, trials asses-
sing different pharmacological procedures, and abstracts
reporting a negative or neutral conclusion. One researcher
(CB), who is an assistant professor in primary care, screened
all retrieved abstracts and selected abstracts following these
inclusion criteria. In cases of doubt regarding the inclu-
sion of an abstract, a second researcher (IB) evaluated the
abstract to achieve consensus.
From the selected reports, the reviewer systematically
extracted the industry funding source and all authors’
financial CoI. If these data were not reported in the abstract
or full-text article, the abstract was excluded.
Of the 2,797 citations screened, reports of 75 RCTs
were selected [see Additional files 2 and 3]. In 29 reports
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(37%), all authors had financial CoI. In 62 (81%), more than
50% of the authors had financial CoI. In 58 (77%), authors
who had financial CoI were industry employees and were
the first, second or last author in 34 (45%) reports.
Abstract construction
The abstracts for all selected RCTs were standardized
and modified. The journal name, date and registration
number at ClinicalTrials.gov were deleted. Authors' names
were substituted by names randomly selected among
the 200 names most common in the United Kingdom
[see Additional file 4]. Treatments were referred to as
‘experimental treatment A’ or ‘experimental treatment B’.
Acronyms used for the study were deleted and dates in the
text were modified to avoid trial recognition. Furthermore,
each abstract was translated into French. As a quality
procedure, three GPs read all abstracts to ensure the quality
of the translation and the relevance of the abstracts for GPs.
The abstract for each RCT was reported in three
formats as follows:
– Abstract with no mention of the funding source or
CoI. If the funding was reported in the original
abstract, it was removed.
– Abstract reporting the funding source only. A heading
‘FUNDING’ was added after the abstract conclusions.
Under this heading, we reported the name of the
pharmaceutical industry funding the trial.
– Abstract reporting the funding source and CoI. Two
headings were added after the abstract conclusions.
Under the first heading ‘FUNDING’, we reported the
name of the pharmaceutical industry funding the
trial. Under the second heading ‘CONFLICTS OF
INTEREST,’ we reported the initials of authors who
1) were employed by the industry and 2) had a
financial interest and/or other relationship with the
industry (for example, fees, travel costs, stock options,
link with a family member employed by the industry).
The number of authors with CoI varied in the RCT
reports (for 37% of abstracts, all authors had financial
CoI; for 81%, more than 50% of authors had
financial CoI; for 45%, the first, second or last
author was employed by the pharmaceutical
industry) (see examples in Table 1).
Consequently, we had 225 versions of the 75 abstracts
selected: 75 with no mention of the funding source or CoI,
75 reporting the funding source only, and 75 reporting the
funding source and CoI.
Selection of general practitioners and recruitment procedures
Eligible participants were French GP members of a net-
work of GPs involved in clinical research. GPs were from
all over France and had part-time activity in a university
general practice department as a teacher or student
supervisor.
GPs were invited by email to participate in a study
evaluating the interpretation of abstracts of RCTs
(with three reminders) or by an investigator during the
national annual medical congress for general practice. We
used two different sources of recruitment for pragmatic
reasons. Such a strategy is very often used in most RCTs
to increase the sample size and the generalizability of the
study results. The GPs were informed that their participa-
tion would involve reading only one abstract of an RCT
and answering some questions about their interpretation
of the abstract. They were informed that the collected data
would remain anonymous and that we would inform them
of the study results when available. However, they
did not know that abstracts were modified and that
several formats were compared. As approved by the
ethics committee, participant consent was considered
obtained as soon as they logged onto the survey site. If
GPs agreed to participate, they had to complete a
questionnaire related to their general characteristics.
They were instructed to carefully read one abstract
that was randomly selected for them and they had to
answer questions related to their interpretation of this
abstract (see Outcomes and Additional files 5 and 6).
Randomization and blinding of general practitioners
An independent statistician created a computerized
randomization list with a 1:1:1 ratio using random
block sizes. The sequence was generated to have the same
number of assessments for each of the three formats
of a given abstract. A computer engineer uploaded the
randomization list to a secure Internet system to assure
allocation concealment. Participants logged onto this se-
cure Internet system and were randomized to assess one
of the 75 abstracts presented in one of the three formats.
Participants were informed that the aim of the study
was to assess their interpretation of RCT abstracts, but
they did not know that abstracts were modified and that
several formats were compared.
Outcomes
The primary outcome was GPs’ confidence in the ab-
stract’s conclusions. GPs answered the following ques-
tion: ‘On a scale ranging from 0 to 10, indicate your
confidence in the conclusion reported,’ with 0, not at
all confident, to 10, completely confident. The secondary
endpoints were the perceived methodological quality of
the study and the interpretation of the treatment benefit
in terms of safety and efficacy. For these outcomes, GPs
were asked ‘On a scale ranging from 0 to 10, what is the
methodological quality of the study?’ with 0, very poor
quality, to 10, excellent quality, and ‘On a scale ranging
from 0 to 10, is the experimental treatment beneficial in
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Table 1 Examples of abstracts assessed
Abstract with no mention of funding source and CoI Abstract reporting funding source only Abstract reporting funding source and CoI
Efficacy and safety of experimental treatment A in
combination with treatment B and treatment c in patients
with mixed dyslipidemia.
Efficacy and safety of experimental treatment A in
combination with treatment B and treatment c in patients
with mixed dyslipidemia.
Efficacy and safety of experimental treatment A in
combination with treatment B and treatment c in patients
with mixed dyslipidemia.
AUTHORS: Thomson MR; Cook A; Pettigrew GE; Bower G;
Bishop D; Potter LM; Alyn JC
AUTHORS: Thomson MR; Cook A; Pettigrew GE; Bower G;
Bishop D; Potter LM; Alyn JC
AUTHORS: Thomson MR; Cook A; Pettigrew GE; Bower G;
Bishop D; Potter LM; Alyn JC
BACKGROUND: Treatment B and treatment C combination
therapy may be insufficient to improve lipid and nonlipid
parameters beyond low-density lipoprotein cholesterol
(LDL-C) in patients with mixed dyslipidemia.
BACKGROUND: Treatment B and treatment C combination
therapy may be insufficient to improve lipid and nonlipid
parameters beyond low-density lipoprotein cholesterol
(LDL-C) in patients with mixed dyslipidemia.
BACKGROUND: Treatment B and treatment C combination
therapy may be insufficient to improve lipid and nonlipid
parameters beyond low-density lipoprotein cholesterol (LDL-C)
in patients with mixed dyslipidemia.
METHODS: In this phase 3, multicenter, double-blind study,
a total of 543 patients with triglycerides >/=150 mg/dL
and <400 mg/dL, high-density lipoprotein cholesterol
(HDL-C) <40 mg/dL (<50 mg/dL for women), and LDL-C
>/=130 mg/dL were randomized to 12 weeks of treatment
with experimental treatment A 135 mg or placebo, each
coadministered with treatment B 40 mg + treatment C
10 mg (treatment BC).
METHODS: In this phase 3, multicenter, double-blind study,
a total of 543 patients with triglycerides >/=150 mg/dL
and <400 mg/dL, high-density lipoprotein cholesterol
(HDL-C) <40 mg/dL (<50 mg/dL for women), and LDL-C
>/=130 mg/dL were randomized to 12 weeks of treatment
with experimental treatment A 135 mg or placebo, each
coadministered with treatment B 40 mg + treatment C
10 mg (treatment BC).
METHODS: In this phase 3, multicenter, double-blind study,
a total of 543 patients with triglycerides >/=150 mg/dL
and <400 mg/dL, high-density lipoprotein cholesterol (HDL-C)
<40 mg/dL (<50 mg/dL for women), and LDL-C >/=130 mg/dL
were randomized to 12 weeks of treatment with experimental
treatment A 135 mg or placebo, each coadministered with
treatment B 40 mg + treatment C 10 mg (treatment BC).
RESULTS: Both treatment regimens lowered LDL-C by >50%;
however, experimental treatment A and treatment BC resulted
in significantly (P < .001) greater improvements in HDL-C
(13.0% vs 4.2%), triglycerides (-57.3% vs -39.7%), non-HDL-C
(-55.6% vs -51.0%), and apoprotein B (-49.1% vs -44.7%)
compared with treatment BC. Overall, adverse events were
similar in the 2 treatment groups. No unexpected muscle,
hepatic, or renal safety signals were identified with either
treatment combination.
RESULTS: Both treatment regimens lowered LDL-C by >50%;
however, experimental treatment A and treatment BC resulted
in significantly (P < .001) greater improvements in HDL-C
(13.0% vs 4.2%), triglycerides (-57.3% vs -39.7%), non-HDL-C
(-55.6% vs -51.0%), and apoprotein B (-49.1% vs -44.7%)
compared with treatment BC. Overall, adverse events were
similar in the 2 treatment groups. No unexpected muscle,
hepatic, or renal safety signals were identified with either
treatment combination.
RESULTS: Both treatment regimens lowered LDL-C by >50%;
however, experimental treatment A and treatment BC resulted
in significantly (P < .001) greater improvements in HDL-C
(13.0% vs 4.2%), triglycerides (-57.3% vs -39.7%), non-HDL-C
(-55.6% vs -51.0%), and apoprotein B (-49.1% vs -44.7%)
compared with treatment BC. Overall, adverse events were
similar in the 2 treatment groups. No unexpected muscle,
hepatic, or renal safety signals were identified with either
treatment combination.
CONCLUSIONS: In patients with mixed dyslipidemia, the
combination of experimental treatment A + treatment BC
significantly improved lipid and nonlipid parameters
compared with treatment BC and was generally well tolerated.
CONCLUSIONS: In patients with mixed dyslipidemia, the
combination of experimental treatment A + treatment BC
significantly improved lipid and nonlipid parameters
compared with treatment BC and was generally well tolerated.
CONCLUSIONS: In patients with mixed dyslipidemia, the
combination of experimental treatment A + treatment BC
significantly improved lipid and nonlipid parameters
compared with treatment BC and was generally well tolerated.
FUNDING: Abbott. FUNDING: Abbott.
CONFLICTS OF INTEREST: MRT, AC and GEP declared
financial interest and/or other relationships with Abbott. GB,
DB, LMP and JCA are employees of Abbott.
CoI, conflicts of interest.
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terms of safety and efficacy?’ with 0, not at all beneficial,
to 10, totally beneficial.
Details of the questionnaire are in Additional file 6.
Sample size
With a significance level of 1.67% fixed for each of the three
2 × 2 comparisons (Bonferroni correction to maintain an
overall significance level of 5%), we needed 118 evaluations
for each format to demonstrate an effect size of 0.5 on the
numeric scale with a power of 90% for each 2 × 2 compari-
son. Because we expected that each participant would read
a single abstract, we needed to include 118 participants per
arm (354 in total).
Statistical analysis
Descriptive results are reported with means and stand-
ard deviations (SDs), median and interquartile ranges
(Q1 to Q3) for quantitative variables and frequencies and
percentages by modality for qualitative variables.
We had three main comparisons: abstracts with no men-
tion of the funding source or CoI versus reporting the fund-
ing source only; abstracts with no mention of the funding
source or CoI versus reporting the funding source and CoI;
and abstracts reporting the funding source only versus
reporting the funding source and CoI. Differences in pri-
mary outcome between groups were estimated by a linear
model and were compared by Tukey’s honestly significant
difference test to adjust for multiple testing [26]. Differences
in secondary outcomes were compared in the same manner
as for the primary outcome. Post hoc sensitivity analysis
adjusted on the mode of recruitment were performed. All
analyses involved use of R software v3.0.1 [27].
Results
General practitioner characteristics
The flow of participants is shown in Figure 1. Between
October 2012 and June 2013, among 605 GPs contacted,
354 (58%) agreed to participate, and 118 were allocated to
each arm. The characteristics of GPs are given in Table 2.
In all, 65% were men; the median (Q1 to Q3) age was
51 (36 to 57). Less than half (43%) had participated in a
pharmaceutical industry–funded clinical trial. Only 22%
had received some fees from the pharmaceutical industry
for speaking, consulting or enrolling patients in trials. Half
had not received any visits from pharmaceutical industry
representatives.
General practitioners’ confidence in abstract conclusions
Abstracts were read by a median of six GPs (Q1 to Q3, 3
to 6). In all, 34 abstracts were read three times (once in
each group), 39 were read six times (twice in each group)
and two were read nine times (three times in each group).
Data on the mean (SD) GP confidence in abstract con-
clusions are reported in Table 3. The mean difference
(95% confidence interval (CI)) in confidence with con-
clusions was 0.2 (−0.6; 1.0) (P = 0.84) for abstracts
reporting the funding source only versus no funding
source or CoI; −0.4 (−1.3; 0.4) (P = 0.39) for abstracts
reporting the funding source and CoI versus no funding
source or CoI; and −0.6 (−1.5; 0.2) (P = 0.15) for abstracts
reporting the funding source and CoI versus the funding
source only (Table 3). The adjusted post-hoc analysis did
not obtain exactly the same results as the analysis that was
not adjusted on the mode of recruitment. However the
adjusted results were very consistent and confirm that
the results are robust (see Additional file 7).
General practitioners’ perception of trial methodological
quality and treatment benefit
The mean difference (95% CI) in perception of quality was
0.1 (−0.7; 0.9) (P = 0.97) for abstracts reporting the fund-
ing source only versus no funding source or CoI; −0.4
(−1.2; 0.4) (P = 0.41) for abstracts reporting the funding
source and CoI versus no funding source or CoI; and −0.5
(−1.3; 0.3) (P = 0.30) for abstracts reporting the funding
source and CoI versus the funding source only (Table 3).
The mean difference (95% CI) in assessment of treat-
ment benefit was −0.1 (−1.0; 0.7) (P = 0.93) for abstracts
reporting the funding source only versus no funding source
or CoI; −0.8 (−1.7; 0.02) (P = 0.06) for abstracts reporting
the funding source and CoI versus no funding source
or CoI; and −0.7 (−1.5; 0.1) (P = 0.13) for abstracts
reporting the funding source and CoI versus the funding
source only (Table 3).
Discussion
This RCTassessed the impact of reporting a funding source
and/or financial CoI in trial report abstracts on GPs’ inter-
pretation of trial results reported in the abstracts’ conclu-
sions. We used a large representative sample of abstracts of
RCTs indexed in PubMed but did not find a statistically
significant difference in GPs’ confidence in the abstracts’
conclusions, assessment of trial methodological quality or
perception of treatment benefit.
Although one study showed that physicians were not
influenced by disclosure statements in trial reports
[25], most studies evaluating how physicians interpret
research funding disclosures showed that abstracts
reporting a funding source or CoI could modify readers’
interpretation [22-24]. In contrast, our results did not
show a statistically significant difference in GPs’ inter-
pretation of an abstract’s findings by the disclosure
statements. However, our confidence intervals were
wide, with an effect going in the same direction, and
confidence in abstract conclusions was surprisingly low,
3.6 on a scale from 0 to 10. Therefore, we cannot exclude
an effect, particularly for abstracts reporting both a funding
source and authors’ CoI.
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Previous studies evaluated physicians’ interpretation of
specifically developed vignettes or abstracts of hypothetical
trials [22,24] or used the abstract of a single trial [23].
Contrary to these studies, we aimed to have a pragmatic
approach and used abstracts from a large sample of real
trials. We selected a representative sample of abstracts of
RCT reports published in 2010 and indexed in PubMed,
and we systematically recorded the funding source and au-
thors’ CoI for these trials. To avoid bias, all information that
could allow readers to identify the trial or drug investigated
Table 2 General characteristics of general practitioner (GP) evaluators of abstracts of randomized controlled trials of
pharmaceutical treatments
GP characteristics All GPs
number = 354
Abstracts with no mention
of funding source or CoI
number = 118
Abstracts reporting
funding source only
number = 118
Abstracts reporting
funding source and
CoI number = 118
Gender (male) - number (%) 227 (64.9) 78 (66.7) 76 (65.5) 73 (62.4)
Age, years - median (Q1 to Q3) 51.4 (36.4; 57.3) 48.7 (37.1; 56.3) 51.8 (36.2; 57.6) 52.7 (37.4; 57.2)
Receive fees from pharmaceutical industry - number (%) 75 (21.6) 30 (26.3) 20 (17.1) 25 (21.6)
For performing a presentation 22 (6.3) 8 (7.0) 7 (6.0) 7 (6.0)
For consulting 16 (4.6) 4 (3.5) 6 (5.1) 6 (5.2)
For enrolling patients in a trial 60 (17.3) 26 (22.8) 18 (15.4) 16 (13.8)
Participate (current or past) in a trial funded by
pharmaceutical industry – number (%)
151 (43.5) 54 (47.4) 47 (40.2) 50 (43.1)
Receive visits from medical representatives of
pharmaceutical industry - number (%)
None 174 (50.1) 56 (49.1) 59 (50.4) 59 (50.9)
1 to 5 per month 84 (24.2) 30 (26.3) 25 (21.4) 29 (25.0)
6 to 10 per month 54 (15.6) 17 (14.9) 21 (17.9) 16 (13.8)
>10 per month 35 (10.1) 11 (9.6) 12 (10.3) 12 (10.3)
CoI, conflicts of interest.
CoI, conflicts of interest
Analyzed
n= 118
Invited to participate n= 605
Did not participate n= 247
118 allocated to abstracts 
reporting funding source only
118 allocated to abstracts 
reporting funding source and 
CoI 
118 allocated to abstracts with 
no mention of funding source 
and CoI
Analyzed
n= 118
Analyzed
n= 118
Randomization n= 354
Logged on but did not enter any data n= 4
Looged on n= 358
Figure 1 Flow diagram of general practitioner evaluators in the study.
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Table 3 Comparison of GPs’ confidence in the abstract’s conclusions, methodological quality and treatment benefit
Abstracts with no
mention of funding
source or CoI
number = 118
Abstracts reporting
funding source only
number = 118
Abstracts reporting
funding source and
CoI number = 118
Abstracts reporting funding
source only versus no
mention of funding
source or CoI
Abstracts reporting
funding source and CoI
versus no mention of
funding source or CoI
Abstracts reporting
funding source and CoI
versus funding source only
Outcomes Mean (SD) Mean (SD) Mean (SD) Mean difference (95%CI) Mean difference (95%CI) Mean difference (95%CI)
Confidence in the abstract
conclusions (scale 0 to 10)
3.6 (2.6) 3.8 (2.6) 3.2 (2.7) 0.2 (−0.6; 1.0), P = 0.84 −0.4 (−1.3; 0.4), P = 0.39 −0.6 (−1.5; 0.2), P = 0.15
Methodological quality of
the study (scale 0 to 10)
4.5 (2.7) 4.6 (2.5) 4.1 (2.6) 0.1 (−0.7; 0.9), P = 0.97 −0.4 (−1.2; 0.4), P = 0.41 −0.5 (−1.3; 0.3), P = 0.30
Treatment benefit in
terms of efficacy and
safety (scale 0 to 10)
5.0 (2.8) 4.8 (2.7) 4.1 (2.8) −0.1 (−1.0; 0.7), P = 0.93 −0.8 (−1.7; 0.02), P = 0.06 −0.7 (−1.5; 0.1), P = 0.13
The confidence in abstract’s conclusions is evaluated on a 0, (not at all), to 10, (completely confident) scale.
The methodological quality of the study is evaluated on a 0, (very poor), to 10, (excellent quality) scale.
Treatment benefit is evaluated on a 0, (not at all), to 10, (completely confident) scale.
Differences in outcomes between groups were estimated using a linear model and were compared with a Tukey’s HSD test [26]. CI, confidence interval; CoI, conflicts of interest; GP, general practitioner; HSD, honestly
significant difference; SD, standard deviation.
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9
was deleted or modified by using, for example, ficti-
tious names for authors. Abstracts reporting a nega-
tive or neutral conclusion were not included so as
to homogenize abstract conclusions and facilitate the
interpretation of our results.
In this trial, we evaluated the reporting of both a funding
source and authors’ CoI in abstracts for several reasons.
First, we focused on abstracts because they are an essential
mode for disseminating research results [28-30]. Fur-
thermore, the CONSORT statement for abstracts clearly
recommends reporting the funding source to improve
transparency, but we lack a clear recommendation on
the reporting of authors’ financial CoI in abstracts. CoI
are defined by a set of circumstances that create a risk
that professional judgment or actions regarding a pri-
mary interest will be unduly influenced by a secondary
interest [31]. CoI are divided into various categories,
from financial to non-financial ties, such as personal
relationships [32]. In our study, we did not specifically
assess CoI other than financial ones. Furthermore, we
explored only one factor – reporting funding source
and CoI disclosure – and we acknowledge that in most
cases, a multifaceted type of approach is required to
change attitudes and behavior.
Our study has some limitations. First, in the context of
a study on the interpretation of abstract results, GPs
might not have interpreted abstracts as they usually do
in clinical practice. Evaluation of how carefully the GPs
read the abstract was not done as this is difficult to ap-
praise. Anonymization of abstracts may have distanced
the reader and contributed to the low confidence in the
abstracts. As well, the low confidence overall suggests that
GPs were more suspicious than usual, by searching details
with attention. Second, these results may not be applicable
to all physicians. The participants in this study were GPs
involved in clinical research and/or with part-time activity
in a university general practice department as a teacher or
student supervisor. Our participants probably have higher
expertise in clinical research than the usual French GP.
Finally, this study was planned to detect a large effect, and
confidence intervals were wide. Therefore, we cannot
exclude a smaller effect [33], particularly for abstracts
reporting both a funding source and authors’ CoI.
Conclusions
In conclusion, we found no statistically significant difference
in GPs’ interpretations of findings from abstracts reporting
the funding source and/or CoI for RCTs investigating
pharmaceutical treatments. However, the mean differ-
ences between sets of abstracts had wide confidence
intervals and we cannot exclude a possible impact of
reporting the funding source and CoI on readers’ inter-
pretation, particularly for abstracts reporting both the
funding source and authors’ financial CoI.
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